#United States #Boston #Palatin Technologies #Diabetic Nephropathy #Melanocortin Agonist

Palatin Technologies Presents Positive Findings on Diabetic Kidney Disease

Palatin Technologies, Inc., a biopharmaceutical firm focused on innovative medicines utilizing the melanocortin receptor system, announced notable findings from its Phase 2b BREAKOUT study aimed at addressing diabetic kidney disease. This groundbreaking data was revealed at the National Kidney Foundation Spring Meeting held in Boston, MA. The study evaluates the efficacy of Bremelanotide (BMT) in stabilizing kidney function in adult patients suffering from Type 2 diabetic nephropathy.

During the presentation, Dr. James A. Tumlin, the CEO of NephroNet Clinical Trials Consortium and lead investigator of the study, outlined several important outcomes from the trial. Notably, the six-month open-label study involved 16 patients with confirmed Type 2 diabetic nephropathy who exhibited significant markers of kidney damage.

The findings emphasized the following key results:

• - 71% of participants experienced a greater than 30% reduction in urine protein to creatinine ratio (UP/Cr), a crucial sign of kidney distress.
• - 71% displayed improvement or stabilization in their estimated glomerular filtration rate (eGFR), an important parameter for evaluating kidney performance.
• - 37.5% recorded elevated urinary vascular endothelial growth factor (VEGF) levels, indicating enhanced vascular support in the kidneys.
• - 36% showed reduced urinary losses of synaptopodin, reflecting healthier kidney structure and cell function.

According to Carl Spana, Ph.D., President and CEO of Palatin, the positive results mark the company's third significant clinical achievement across various therapeutic domains. This momentum is indicative of the efficacy of their melanocortin platform, which has shown promising results across diverse conditions such as obesity, ulcerative colitis, and dry eye disease.

The BREAKOUT study enrolled patients with a UP/Cr ratio exceeding 1000 mg/g and required active monitoring through a follow-up phase. Each subject received a low-dose of Bremelanotide administered subcutaneously twice daily, combined with their optimal levels of RAAS inhibition therapy.

The implications of this data are profound, as diabetic nephropathy remains a leading cause of end-stage renal disease (ESRD). With approximately 30 million individuals in the United States afflicted by chronic kidney disease largely driven by Type 2 diabetes and hypertension, innovating therapeutic approaches can mitigate the risks of disease progression.

Dr. Tumlin’s insights into podocyte health underscore that preserving podocyte function is critical for maintaining kidney integrity. This aligns with emerging evidence indicating that targeted treatments aiming at podocyte survival could revolutionize the standard of care for diabetic nephropathy.

Ultimately, the melanocortin receptor system plays a versatile role in modulating various physiological responses, including inflammation, metabolism, and immune system interactions. The potential for agonists like Bremelanotide to harness these pathways is particularly noteworthy, especially in the context of complex conditions like diabetic nephropathy.

The poster featuring these findings will be showcased at the Spring Meeting and can also be accessed online on Palatin’s official website. As Palatin aims to further its research and development efforts, this pivotal data underscores their commitment to addressing significant unmet medical needs.

For additional details about Palatin Technologies and its innovative product pipeline, visit www.Palatin.com or follow updates on Twitter @PalatinTech.